Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec 2;20(1):269.
doi: 10.1186/s12931-019-1237-1.

Relationship between diffusion capacity and small airway abnormality in COPDGene

Rachel N Criner  1 , Charles R Hatt  2   3 , Craig J Galbán  3 , Ella A Kazerooni  3 , David A Lynch  4 , Meredith C McCormack  5 , Richard Casaburi  6 , Neil R MacIntyre  7 , Barry J Make  8 , Fernando J Martinez  9 , Wassim W Labaki  10 , Jeffrey L Curtis  10   11 , Mei Lan K Han  10
Affiliations

Relationship between diffusion capacity and small airway abnormality in COPDGene

Rachel N Criner et al. Respir Res. .

Abstract

Impaired single breath carbon monoxide diffusing capacity (DLCO) is associated with emphysema. Small airways disease (SAD) may be a precursor lesion to emphysema, but the relationship between SAD and DLCO is undescribed. We hypothesized that in mild COPD, functional SAD (fSAD) defined by computed tomography (CT) and Parametric Response Mapping methodology would correlate with impaired DLCO. Using data from ever-smokers in the COPDGene cohort, we established that fSAD correlated significantly with lower DLCO among both non-obstructed and GOLD 1-2 subjects. The relationship between DLCO with CT-defined emphysema was present in all GOLD stages, but most prominent in severe disease. TRIAL REGISTRATION: NCT00608764. Registry: COPDGene. Registered 06 February 2008, retrospectively registered.

Keywords: Chronic obstructive pulmonary disease (COPD); Diffusing capacity of the lung (DLCO); Parametric response mapping (PRM); Small airways disease (SAD).

PubMed Disclaimer

Conflict of interest statement

RNC, EAK, NM, RC, WWL – none.

CRH – An employee of and has stock options in Imbio LLC, which has licensed the PRM technology for use as FDA-approved commercial software.

DAL - Reports grants from NHLBI and has a pending patent entitled Systems and Methods for Classifying Severity of COPD.

CJG – Is co-inventor of PRM, which is licensed to Imbio by the University of Michigan.

MM – Reports other support from UpToDate.

BM – Reports funding from the NHLBI for the COPDGene study; grants and medical advisory boards from Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, and Sunovian; personal fees for DSMB from Spiration and Shire/Baxalta; CME personal fees from WebMD, National Jewish.

Health, American College of Chest Physicians, Projects in Knowledge, Hybrid Communications, SPIRE Learning, Ultimate Medical Academy, Catamount Medical, Eastern Pulmonary Society, Catamount Medical Communications Medscape, Eastern VA Medical Center, Academy Continued Healthcare Learning, and Mt. Sinai Medical Center; royalties from Up-To-Date; medical advisory boards from Novartis, Phillips, Third Pole, Science 24/7, and Vernoa; and grants from Pearl.

FJM - Receives personal fees and non-financial support from American College of Chest Physicians, AstraZeneca, Boehringer Ingelheim, ConCert, Genentech, GlaxoSmithKline, Inova Fairfax Health System, Miller Communications, National Association for Continuing Education, Novartis, Pearl Pharmaceuticals, PeerView Communications, Prime Communications Puerto Rican Respiratory Society, Chiesi, Sunovion, Theravance, Physicians Education Resource, Canadian Respiratory Network, Teva, and Dartmouth. Receives non-financial support from ProterrixBio, Gilead, Nitto, Potomac, University of Alabama Birmingham, and Zambon. Receives personal fees from Columbia University, Integritas, MD Magazine, Methodist Hospital Brooklyn, New York University, UpToDate, WebMD/MedScape, Western Connecticut Health Network, Patara/Respivant, PlatformIQ, American Thoracic Society, Rockpointe, Rare Disease Healthcare Communications, and France Foundation. He receives grants from the NIH. He also receives other support from Afferent/Merck, Biogen, Veracyte, Prometic, Bayer, Bridge Biotherapeutics, and ProMedior.

JLC - Reports grants from NIH/NHLBI, NIH/NIAID, the Department of Veterans Affairs, and the Department of Defense.

MKH - Reports grants from NIH, personal fees from BI, GSK, AZ, and Mylan. She also receives other support from Novartis and Sunovion.

References

    1. Hogg JC, Macklem PT, Thurlbeck WM. Site and nature of airway obstruction in chronic obstructive lung disease. N Engl J Med. 1968;278:1355–1360. doi: 10.1056/NEJM196806202782501. - DOI - PubMed
    1. McDonough JE, Yuan R, Suzuki M, Seyednejad N, Elliott WM, Sanchez PG, Wright AC, Gefter WB, Litzky L, Coxson HO, et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med. 2011;365:1567–1575. doi: 10.1056/NEJMoa1106955. - DOI - PMC - PubMed
    1. Koo HK, Vasilescu DM, Booth S, Hsieh A, Katsamenis OL, Fishbane N, Elliott WM, Kirby M, Lackie P, Sinclair I, et al. Small airways disease in mild and moderate chronic obstructive pulmonary disease: a cross-sectional study. Lancet Respir Med. 2018;6:591–602. doi: 10.1016/S2213-2600(18)30196-6. - DOI - PubMed
    1. D'Anna SE, Asnaghi R, Caramori G, Appendini L, Rizzo M, Cavallaro C, Marino G, Cappello F, Balbi B, Di Stefano A. High-resolution computed tomography quantitation of emphysema is correlated with selected lung function values in stable COPD. Respiration. 2012;83:383–390. doi: 10.1159/000329871. - DOI - PubMed
    1. Vasilescu DM, Martinez FJ, Marchetti N, Galban CJ, Hatt C, Meldrum CA, Dass C, Tanabe N, Reddy RM, Lagstein A, et al. Non-invasive imaging biomarker identifies small airway damage in severe COPD. Am J Respir Crit Care Med. 2019;200:575–581. doi: 10.1164/rccm.201811-2083OC. - DOI - PMC - PubMed

MeSH terms

Substances